News

Routine treatment with Shire‘s Takhzyro (lanadelumab) — given as a 300 mg dose every two weeks — significantly reduces the rate of acute attacks in hereditary angioedema (HAE) patients age 12 and older, a Phase 3 trial shows. The treatment also kept more patients attack-free during the 26-week study, reduced…

Long-term prevention with human formulations of the C1 esterase inhibitor — Cinryze or Haegarda — safely and effectively reduces the number of acute attacks in people with hereditary angioedema (HAE), but the therapies’ prices are too high, according to a report of the Institute for Clinical and Economic Review…

KalVista Pharmaceuticals’ investigational candidate KVD900, being developed for the treatment of hereditary angioedema (HAE), is safe and effectively inhibits kallikrein, the main driver of HAE attacks, results from a Phase 1 clinical trial show. Following these positive results, the company is now launching a larger Phase 2…

Delays between symptom onset and diagnosis of hereditary angioedema (HAE) types 1 and 2 have been decreasing, according to a real-world study that also revealed a younger age at diagnosis in this patient population over time. The study, “Improvement in diagnostic delays over time in patients…

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), favors granting marketing authorization to lanadelumab for routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and older. Shire’s lanadelumab is a monoclonal antibody that specifically binds to…

With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Credit and affordable health insurance to future funding for rare disease research. Yet “whether Democrats take over the House or Senate,…

Despite being more prone to developing heart disease, patients with hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) show normal blood vessel function, a study reveals. The study, “Flow mediated vasodilation assay indicates no endothelial dysfunction in hereditary angioedema patients with C1-inhibitor deficiency,” was published in Annals…

Ruconest (recombinant C1-inhibitor, rhC1-INH) and Firazyr (icatibant) are safe and effective approaches as first-line treatment for hereditary angioedema (HAE) attacks in pregnant women, a study suggests. Findings of the study, “Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy,” were published in the Journal of…

The mother of a 28-year old pregnant woman suspected her daughter had hereditary angioedema after doing an internet search while the daughter was hospitalized. The diagnosis was quickly dismissed by clinicians, who considered it extremely unlikely, but it later proved to be correct. This case report highlights the importance of…

Angioedema seems to predict poorer responses and lower chances of remission in chronic urticaria patients receiving Xolair (omalizumab), a retrospective study shows. The study, “Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: a retrospective study,” was published in the journal…